Rybrevant (Amivantamab-vmjw)

Rybrevant is a bispecific EGF receptor directed and MET receptor-directed antibody used for the treatment of adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon-20 insertion mutations, whose cancer has progressed on or after platinum-based chemotherapy. 

Recommended Dosage: The recommended dosage of rybrevant injection is based on the baseline body weight and administered as an intravenous infusion after dilution.

• For body weight (at baseline) less than 80 kg, recommended dose is 1050 mg (3 vials). 
• For body weight (at baseline) greater than or equal to 80 kg, recommended dose is 1400 mg (4 vials). 

Administer premedications as recommended. Administer via a peripheral line on Week 1 & 2. Administer rybrevant dosage weekly for 4 weeks, with the initial dose as a split infusion in Week 1 on Day 1 & 2, then administer every 2 weeks thereafter. Administer diluted Rybrevant dosage intravenously. 

• Amivantamab can cause infusion-related reactions (IRR). Monitor patients for any signs/symptoms of infusion reactions during infusion in a setting where cardiopulmonary resuscitation medicine and equipment exist. Interrupt infusion in case IRR is suspected. Reduce the infusion rate or permanently interrupt therapy based on severity.
• The rybrevant dosing can cause interstitial lung disease (ILD)/pneumonitis. Assess patients for new or worsening symptoms indicative of ILD/pneumonitis. Promptly withhold this drug in patients with suspected ILD/pneumonitis and permanently interrupt in case ILD/pneumonitis is confirmed. 
• Amivantamab-vmjw can cause dry skin, rash (including dermatitis acneiform), and pruritus. In case skin reactions emerge, initiate topical corticosteroids and topical or oral antibiotics. Quickly refer patients presenting with severe rash, distribution or atypical appearance or lack of improvement within 14 days to a dermatologist. 
• Rybrevant 350 mg treatment can cause ocular toxicity including dry eye symptoms, conjunctival redness, keratitis, blurred vision, ocular itching, visual impairment, and uveitis. Promptly refer patients presenting with eye symptoms to an ophthalmologist. 
• Amivantamab-vmjw can cause fetal harm when administered to a pregnant woman. Females of reproductive age should consider effective contraception during therapy and for 3 months after the final dose of Amivantamab-vmjw.

What documents are required to import RYBREVANT to India?

RYBREVANT (amivantamab-vmjw) injection can be imported by patients or government hospitals on the name of the patients only. 

The following documentation required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients id proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is RYBREVANT available in India?

RYBREVANT (amivantamab-vmjw injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)

• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

RYBREVANT can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of RYBREVANT (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable). 

Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for amivantamab price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Rybrevant®?

Amivantamab-vmjw is Generic Name for the trade name drug Rybrevant®.

What is the Manufacturer Name of Rybrevant®?

Rybrevant® is manufactured by Janssen Pharmaceuticals, Inc.

Is Rybrevant® approved by the FDA?

Yes, Rybrevant® is approved by the FDA. Date of approval: May 21, 2021.

What is Rybrevant®?

Rybrevant is a cancer medication approved to treat adult patients with advanced non-small cell lung cancer (NSCLC) whose cancer cells have certain genetic changes.

What is the dosage and form of Rybrevant® supplied?

Rybrevant® is supplied as Injection: 350 mg/7 mL (50 mg/mL) solution in a single-dose vial for intravenous administration. 

What are the most common side effects due to Rybrevant®? 

Most common side effects due to Rybrevant include: IRR, rash, paronychia, musculoskeletal pain, dyspnea, nausea, constipation, fatigue, edema, stomatitis, vomiting, and cough. 

How much does Amivantamab cost in India?

The amivantamab cost in India is absolutely reasonable. In order to procure this NSCLC medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Rybrevant®?

Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton in order to protect from the light. Do not freeze it.

What are the Highlights of prescribing information for Rybrevant®?

Click Here to download full  Rybrevant prescribing information.